Brian Park, PharmD

All articles by Brian Park, PharmD

FDA Approves Imcivree for Rare Genetic Obesity Disorders

December 2, 2020

The FDA has approved Imcivree™ (setmelanotide; Rhythm Pharmaceuticals) for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency.

Psoriasis

Risankizumab Superior to Secukinumab in Plaque Psoriasis Trial

Brian Park, PharmD

January 16, 2020

AbbVie announced positive topline data from a phase 3 study evaluating the efficacy and safety of risankizumab (Skyrizi) compared with secukinumab (Cosentyx; Novartis) in adult patients with moderate to severe plaque psoriasis.

Psoriasis

Bimekizumab Beats Adalimumab in Plaque Psoriasis Trial

Brian Park, PharmD

December 11, 2019

UCB announced positive results from the phase 3 BE SURE study of bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis compared with adalimumab.

Next post in Psoriasis

Brian Park, PharmD

All articles by Brian Park, PharmD

FDA Approves Imcivree for Rare Genetic Obesity Disorders

Risankizumab Superior to Secukinumab in Plaque Psoriasis Trial

Bimekizumab Beats Adalimumab in Plaque Psoriasis Trial

In Pediatric Patients, Long-Term Adalimumab Treatment Effective for Reducing Psoriasis Severity